Search API
With just a few weeks left until Spring Break 2026 in the United States, one of Mexico's most popular tourist destinations is facing concerns among travelers.
On February 23, 2026, travelers at Cancun International Airport faced significant disruptions, with dozens of flights delayed or canceled, leaving hundreds stranded amid heightened security measures. Airport officials have confirmed that Cancun International Airport (CUN) remains operational, with no reported closures.
The chaos at CUN stems from broader regional instability, prompting urgent security warnings from the U.S. Embassy in the area.
The disruptions are linked to road blockages and criminal activity across multiple Mexican states, which have indirectly impacted airline operations by complicating crew movements and logistics.
According to the U.S. government, while the most severe flight cancellations have hit airports in Puerto Vallarta and Guadalajara—where roadblocks have led to the suspension of most services—Cancun has not been spared. Reinforced security presence at the airport has helped maintain functionality, but airlines are working to stabilize schedules as ripple effects continue throughout the day.
Compounding the travel woes, the U.S. Embassy in Mexico issued an updated security alert on February 22, 2026, urging American citizens in Cancun and other parts of Quintana Roo state—including Cozumel, Playa del Carmen, and Tulum—to shelter in place until further notice.
The alert cites ongoing security operations, road blockages, and heightened criminal activity as the primary concerns.
The State Department's travel advisory for Quintana Roo remains at Level 2: Exercise Increased Caution, warning of risks from civil unrest. The local U.S. embassy emphasized that while no airports have been closed nationwide, travelers should monitor local media, check road conditions, and keep family informed of their whereabouts.
In addition to security concerns, travelers to Cancun and the surrounding areas in Quintana Roo should be aware of ongoing risks from mosquito-borne illnesses, including dengue, chikungunya, and Zika. These diseases, transmitted primarily by Aedes mosquitoes, have seen varying levels of activity in Mexico over the past two years.
Dengue remains endemic in Mexico, with significant fluctuations in case numbers. In 2025, Mexico reported approximately 141,421 totalcases, resulting in 85 deaths nationwide.
Quintana Roo and neighboring states such as Veracruz and Sonora accounted for a notable share of cases last year.
As of early 2026 (through epidemiological week 4), Mexico has seen low activity, with 185 confirmed cases and 1,972 probable cases reported in the first two weeks alone.
This is an 83% decrease compared to the same period in 2025, but experts warn of potential seasonal increases as the year progresses.
Chikungunya transmission in Mexico has been sporadic and low in recent years. In 2025, only a handful of cases were documented nationwide, with reports indicating just four confirmed infections, primarily in southern states like Quintana Roo, Chiapas, and Yucatan.
The Pan American Health Organization (PAHO) notes that Zika virus activity in Mexico has declined sharply since the 2015-2016 epidemic. In 2025, only four confirmed cases were reported nationwide, a significant drop from 30 in 2024.
The PAHO says Zika poses particular risks to pregnant women due to potential birth defects.
The U.S. CDC and PAHO emphasize mosquito bite prevention as the primary defense against dengue, chikungunya, and Zika, given the lack of widespread vaccines for all three.
While the World Health Organization recommends the second-generation Qdenga vaccine, it is unavailable in the USA.
However, chikungunya vaccines are available and may be considered for travelers planning extended stays (e.g., 6 months or more) in areas with elevated risk, such as Quintana Roo.
Travelers with underlying health conditions and who are undervaccinated should seek pre-travel medical advice from a travel vaccine expert.
As the safety and health situations in Mexico evolve, travelers are urged to prioritize safety and heed official guidance from both Mexican authorities, the U.S. Embassy, the PAHO, and the CDC.
According to the U.S. Embassy and Consulates in Mexico, due to ongoing security operations, road blockages, and criminal activity, U.S. citizens in several locations in Mexico are advised to shelter in place.
As of February 23, 2026, Security Alert – Update 3 says U.S. government staff in Guadalajara (Jalisco), Puerto Vallarta (Jalisco/Nayarit), Ciudad Guzmán (Jalisco), Cancun (Quintana Roo), Playa del Carmen (Quintana Roo), Cozumel (Quintana Roo), Reynosa (Tamaulipas), Tijuana (Baja California), and Michoacán will shelter in place and work remotely on February 23.
Furthermore, U.S. citizens are encouraged to do the same.
Additionally, all U.S. government staff at the Consulate General in Monterrey have been instructed to remain within the Monterrey metropolitan area and advised not to travel to Mazatlán until Wednesday, February 25, 2026.
Regarding air travel, roadblocks have impacted airline operations, with most domestic and international flights cancelled in both Guadalajara and Puerto Vallarta.
All ride shares are suspended in Puerto Vallarta. Some businesses have suspended operations. And Mexican authorities announced that operations on toll roads in Puebla, Guerrero, Tamaulipas, Nayarit, San Luis Potosi, Tijuana, Queretaro, Veracruz, and Mazatlan will be temporarily curtailed due to blockades that have affected motorists.
These are a few of the actions the U.S. Department of States says people should take: Seek shelter and minimize unnecessary movements, Avoid areas around law enforcement activity, Check @CAPUFE on X for the status of road closures, Monitor local media for updates, Follow the directions of local authorities and in case of emergency, call 911, and Keep family and friends advised of your location and well-being via phone, text, and social media.
Seperately, Texas Governor Greg Abbott urged Texans currently in Mexico, as well as those with family members or friends traveling there, to closely follow warnings from the U.S. Department of State. "Texans' safety is my top priority, whether they are here at home or traveling abroad," said Governor Abbott in a press release.
"I urge all Texans in Mexico to follow the guidance of U.S. officials, stay alert, and ensure they are in contact with the U.S. Embassy or nearest U.S. Consulate. Situations on the ground can change quickly, and staying informed can save lives," added Abbott.
Since August 12, 2025, the State Department has issued Level 4 - Do not travel notices for several Mexican states.
Currently, the U.S. government recommends that you visit your health provider at least 1 month before traveling to Mexico to update your vaccinations.
Puerto Vallarta, a popular beach resort in Mexico that welcomed over six million visitors in 2025, has recently experienced unrest.
Authorities in Puerto Vallarta declared a Code Red alert, advising both residents and tourists to stay indoors.
In response, the U.S. State Department and Global Affairs Canada have issued shelter-in-place travel advisories for Jalisco and nearby regions. As of late February 22, 2026, no tourists or civilians appear to be directly affected by the civil unrest.
However, Puerto Vallarta International Airport has seen multiple flight cancellations, impacting airlines such as Air Canada and WestJet.
While Puerto Vallarta is generally considered safer than other Mexican states, visitors are advised to monitor airline updates, official advisories, and local news, as the situation remains fluid.
The State Department recommends that Americans in Mexico register for the Smart Traveler Enrollment Program, a free service that provides digital alerts in case of an emergency.
According to the U.S. CDC's Travel Health Notices, cases of New World screwworm myiasis, measles, dengue, chikungunya, and malaria have been reported in various Mexican states in early 2026. The CDC suggests prospective travelers to Mexico speak with a travel vaccine advisor about immunization options before departing abroad.
With the global resurgence of the highly contagious measles virus, Southeast Asia is being affected by infected international travelers, including the city-state of the Republic of Singapore. In early 2026, Singapore's Communicable Diseases Agency (CDA) reported a significant increase in measles cases.
Despite historically high vaccination rates, measles remains a significant public health concern in Singapore.
By mid-February 2026, the CDA had recorded 13 confirmed measles cases for the year, including 11 in January alone, surpassing the 11 cases reported for the entire 2024 and nearing the 27 cases seen in 2025.
The CDA emphasized that all of the January cases involved individuals who were not fully vaccinated with the measles, mumps, and rubella (MMR) vaccine.
The vaccine has been compulsory for children since 1985, with the two-dose MMR regimen introduced in 1998.
While Singapore's robust public health system and high baseline coverage have so far limited widespread outbreaks among the six million residents, officials warn that sustained vigilance, including prompt reporting of suspected cases and strong adherence to vaccination, is essential to prevent outbreaks from escalating in our interconnected world.
As of February 22, 2026, proof of measles vaccination is not required for international visitors arriving in Singapore.
Researchers at Stony Brook University have developed an oral vaccine candidate based on a genetically modified, attenuated strain of Listeria monocytogenes. This vaccine stimulates powerful anti-tumor immune responses directly in the gut.
Led by immunologist Brian Sheridan, PhD, the research shows that the vaccine generates tumor-specific CD8+ T cells in the gastrointestinal tract.
In mouse models of colorectal cancer, the oral vaccine significantly improved tumor control, especially when combined with immune checkpoint inhibitors. This combination increases the infiltration of cancer-killing T cells into tumors.
Published on February 5, 2026, in the Journal for ImmunoTherapy of Cancer, the study presents a potential new strategy to overcome immunotherapy resistance in colorectal cancer, which is one of the leading causes of cancer-related deaths worldwide.
"The clinical significance of our laboratory findings is underscored by the vaccine performance in treating established tumors," says Dr. Sheridan. "While this vaccine alone initially curtailed local tumor growth, its true potential was revealed when combined with existing immune checkpoint inhibitors."
"This combination therapy led to profound tumor control in the model and suggests that the vaccine can effectively 'turn on' the immune system in tumors that were previously resistant to standard immune therapy," he explained in a press release.
Furthermore, the method demonstrated that oral immunization combined with immune checkpoint inhibitors induced the accumulation of tumor-specific CD8 T cells within the tumor microenvironment. These specialized immune cells remain stationed in the gut and provide immediate and long-lasting protection against cancer cells, a response not achieved by vaccination or immune checkpoint inhibitors alone.
While the results are promising in preclinical models, human trials will be necessary to assess safety and efficacy.
Seasonal influenza activity remains elevated across much of the United States, though trends vary regionally, with some areas seeing declines in influenza A and rises in influenza B cases.
Unfortunately, the U.S. Centers for Disease Control and Prevention (CDC) has reported six new influenza-associated pediatric deaths in its FluView surveillance update for Week 6 of 2026.
This data highlights the ongoing serious risks posed by the virus to children.
Of the reported deaths on February 14, 2026, five occurred during the current 2025-2026 flu season, bringing the total number of pediatric fatalities this season to 71. These deaths happened during Weeks 2, 4, and 5 (ending January 17, January 31, and February 7, 2026).
Four deaths were linked to influenza A viruses, three of which were subtyped as A(H3N2).
Additionally, one death from the previous 2024-2025 season was reported this week, associated with influenza A(H1N1), bringing that season's final pediatric death total to 290.
Following an update to the U.S. childhood immunization schedule issued by the CDC on January 5, 2026, the annual influenza vaccine for children is now recommended based on shared clinical decision-making between parents or guardians and healthcare providers, rather than as a routine recommendation for all children aged 6 months and older.
Among the children eligible for vaccination and with known vaccination status, approximately 90% of the reported pediatric deaths this season occurred in those who were not fully vaccinated against influenza.
Health officials stress that this approach allows families to consider individual risk factors—such as age, underlying medical conditions, and community flu activity—when deciding whether to vaccinate. The CDC continues to emphasize that flu vaccination remains a crucial prevention tool during ongoing virus circulation.
Vaccination coverage data from the previous 2024-2025 season highlights ongoing challenges: only 50.2% of U.S. children aged 6 months through 17 years received at least one dose of the flu vaccine—the lowest coverage in the past 15 seasons.
As of early February 2026, interim coverage for the current 2025-2026 season stands at approximately 47.5%, similar to the same point last season.
The CDC urges parents to speak with their child's healthcare provider promptly about flu vaccination and to seek early antiviral treatment if flu symptoms develop in high-risk children.
As of February 21, 2026, flu shots remain available at clinics and pharmacies throughout the USA. However, the nasal flu shot is sold out for this season.
As the 2025-2026 influenza season progresses to its later stages, FluMist® —the only nasal spray flu vaccine in the United States—has officially sold out.
The sell-out of FluMist reflects typical end-of-season patterns, as it has a shorter shelf life compared to injectable flu vaccines.
FluMist, a live attenuated influenza vaccine (LAIV), does not require needles and is approved for healthy individuals aged 2 to 49.
According to AstraZeneca's FluMist website, the flu shot is "no longer available to order for the 2025-2026 flu season."
Users are encouraged to sign up for notifications ahead of the next influenza season.
As of February 20, 2026, AstraZeneca has not disclosed exact dose numbers for FluMist, as product-specific distribution and administration data are typically reported after the season ends. In other countries, FluMist® is known as Fluenz® Tetra.
Historically, FluMist has accounted for a smaller market share than injectable alternatives.
A key highlight of this season was the launch of FluMist Home in August 2025, which allowed for self- or caregiver administration.
This direct-to-consumer service enabled eligible individuals to order the vaccine online through a medical screening process, with home delivery in 34 states, covering approximately 80% of the eligible population.
Meanwhile, as the flu season continues to peak in some states, injectable vaccines remain available from healthcare providers and pharmacies across the USA. For the latest updates, visit cdc.gov/flu, flumist.com, or consult your healthcare provider.
Seasonal influenza continues to circulate at elevated levels across the United States in mid-February 2026, with health officials from the Centers for Disease Control and Prevention (CDC) noting a shift in the dominant strains driving infections.
According to the CDC's latest Weekly U.S. Influenza Surveillance Report for 2026, seasonal influenza activity remains high nationally. Influenza A activity is decreasing, while influenza B activity is increasing both nationwide and in most regions of the country. Influenza A(H3N2) viruses have been the most commonly reported subtype this season so far.
However, these trends show notable regional variability.
Regional differences are particularly evident in supplementary tracking tools.
The Walgreens Respiratory Index©, which monitors respiratory illness trends using prescription, testing, and over-the-counter product data from Walgreens locations, illustrates this variability in mid-February 2026.
Numerous states in the eastern portion of the country have shifted to green, indicating lower relative intensity compared to baseline levels. In contrast, states in western areas continue to show red, representing the highest intensity category.
The Index also highlights maximum intensity in several southern states, including Alabama, Arizona, Florida, and Mississippi, where respiratory illness activity—driven largely by ongoing flu circulation—remains at peak levels.
Health experts emphasize that while influenza A declines in many places, the rise in influenza B could sustain elevated activity or lead to prolonged circulation in certain regions.
Officials continue to recommend vaccination.
"This flu season is exceptionally active," commented Anita Patel, vice president of Pharmacy Services Development at Walgreens, in a January 2026 press release.
"To protect yourself and others, I encourage everyone to get vaccinated as soon as possible, wash your hands frequently, and if you're feeling symptoms, get tested right away," Patel says.
The CDC updates its FluView surveillance weekly, and activity levels can fluctuate. For the most current data, visit the CDC's FluView website.
Furthermore, when traveling abroad, check the CDC's Travel Health Notices for information on disease outbreaks in other countries and related travel vaccine options.
